Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting

Nicox SA provided details of poster presentations highlighting data on NCX 470 at the 2024 American Glaucoma Society (AGS) annual meeting, one of the key scientific events in vision research, which was held February 29-March 3, 2024, in Huntington Beach, California.

Poster title: Intraocular Pressure Reduction with NCX 470 versus Latanoprost Across the Spectrum of Baseline Intraocular Pressures 

An analysis of IOP reduction by baseline IOPs demonstrated that in patients with baseline pressures ≤ 28 mmHg, NCX 470 was numerically better at all, and statistical superior at 5/6 timepoints at lowering IOP vs. latanoprost, the current standard of care. Furthermore, NCX 470 provided consistent IOP reduction across the spectrum of baseline IOPs while latanoprost IOP reduction was baseline IOP-dependent.

Poster title: Intraocular Pressure Reduction with NCX 470 versus Latanoprost In Previously Treated Versus Treatment-Naïve Patients

In a pre-planned analysis, we tested whether being on previous IOP lowering medications had an impact on the IOP lowering of NCX 470. Previously treated subjects had greater IOP lowering vs. latanoprost at all timepoints but not by a clinically significant margin. Differences in IOP lowering between treatments were minimal in previously untreated patients. Whether previously treated or treatment naïve-should not impact the selection of NCX 470 versus latanoprost in the treatment of OAG or OHT.

The posters are available on Nicox’s website in the section Publications.

NCX 470, a novel NO-donating bimatoprost eye drop, is currently in phase 3 clinical development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. Results of Mont Blanc, the first of the two phase 3 clinical trials, were announced in October 2022. The second phase 3 clinical trial, Denali, is currently ongoing, and the results are expected in 2025.